Cropped, spliced image leads to a PLOS One correction

Screen Shot 2015-10-01 at 4.27.21 PMA PLOS One paper on morphine treatment for cancer cells has a couple issues with figures, prompting a massive correction — what we affectionately call a “mega-correction” — by the journal.

In one figure, there was “an undisclosed splice.” Another figure contained two panels that were “mistakenly from the same sample.”

The 2013 paper in question, “Chronic Morphine Treatment Attenuates Cell Growth of Human BT474 Breast Cancer Cells by Rearrangement of the ErbB Signalling Network,” has been cited four times, according to Thomson Scientific’s Web of Knowledge.

Here’s the correction:

Continue reading Cropped, spliced image leads to a PLOS One correction

Stem cell researcher who sued Harvard, Brigham & Women’s is leaving his post

anversa
Piero Anversa
A stem cell researcher who sued his employers, Harvard and Brigham & Women’s Hospital, is headed to Switzerland.

Piero Anversa‘s departure follows the dismissal of his suit last summer. Anversa filed the suit with colleague Annarosa Leri, claiming that an investigation into their work damaged their reputations:

they lost a multimillion-dollar offer to purchase their company, Autologous/Progenital; and both Plaintiffs have had possible employment offers at several institutions postponed.

Anversa’s lawyer, Tracey Miner, confirmed that he was moving:

Continue reading Stem cell researcher who sued Harvard, Brigham & Women’s is leaving his post

Irish university strips student of PhD following investigation

maynoothMaynooth University has revoked a former student’s PhD following an investigation into the circumstances that led to two previous retractions in the Journal of Biological Chemistry.

During the investigation, Aisha Qasim Butt admitted to some misconduct in the two papers and the research that made up her PhD, according to a university statement (which you can read in full here): Continue reading Irish university strips student of PhD following investigation

Mol bio paper pulled by PLOS following investigation into figures

Screen Shot 2015-11-17 at 11.58.47 AMPLOS Biology has retracted a paper about the molecular details of β-catenin expression following an investigation by the first author’s institution in Italy.

The investigation, by the Istituto Nazionale per la Ricerca sul Cancro, found that there were multiple “figure anomalies.” According to the note:

An explanation of inadvertent error was given for some of the issues identified, while for two issues, a satisfactory explanation could not be provided.

First author Roberto Gherzi says none of his co-authors helped prepare the figures. The authors maintain that the conclusions are unaffected, but that assurance wasn’t enough for the journal. Here’s more from the lengthy retraction note, which provides some backstory on the “serious concerns” regarding the data:

Continue reading Mol bio paper pulled by PLOS following investigation into figures

MD Anderson researcher Aggarwal up to six corrections

cover (2)A highly cited cancer researcher at MD Anderson has notched three major corrections, all associated with problems in figures. One note cites “human error” as the cause.

Bharat Aggarwal is the last author on all three papers. He is now up to six corrections, two unexplained withdrawals, and two Expressions of Concern. He’s also threatened to sue us in the past, and has told us that his institution has been looking into his work.

Only one note specifies that the correction does not affect the paper’s conclusions.

First up: “Inhibition of growth and survival of human head and neck squamous cell carcinoma cells by curcumin via modulation of nuclear factor-κB signaling,” published in the International Journal of Cancer and cited 168 times, according to Thomson Scientific’s Web of Knowledge. The issues span two figures, according to the erratum note:

Continue reading MD Anderson researcher Aggarwal up to six corrections

“Carelessness” forces Science to correct paper about immune booster

F1.medium (1)

Science is fixing images in a paper published online in April that discovered an immune-boosting protein, after the authors mistakenly mixed up similar-looking Western blots.

The paper, which received some press coverage, identified a protein that helped the immune system fight off cancers and infections. Philip Ashton-Rickardt, a scientist at Imperial College London who led the study, told the The Telegraph:

This is exciting because we have found a completely different way to use the immune system to fight cancer.

The editor in chief of Science, Marcia McNutt, told us that the journal contacted the authors once it learned of “irregularities” in some of the figures, which did not affect the conclusions of the paper:

A bacterium may be anti-fungal, but it’s not anti-retraction

6

The authors of a paper on an anti-fungal bacterium couldn’t ward off a very common problem: plagiarism. The people credited on the paper, published in Applied Microbiology and Biotechnology, apparently weren’t the original authors, according to the retraction note.

We’re not sure who the original authors are. The retraction note doesn’t elaborate much:

Continue reading A bacterium may be anti-fungal, but it’s not anti-retraction

Genetics paper retracted for using material “without permission and/or proper reference”

Molecular Genetics and GenomicsA review article about a tool used to link genes to traits and behaviors has been retracted for including content “without permission and/or proper reference.”

Corresponding author Ali Masoudi-Nejad at the University of Tehran told us that the retraction occurred mostly because the paper included many figures and tables from other sources, and he didn’t realize they needed to seek permission from both the author and the copyright-holder (ie, the publisher). He added that he doubts he is the only one to make this mistake: Continue reading Genetics paper retracted for using material “without permission and/or proper reference”

Intellectual property issues sink cancer paper in JACS

176 spine minimum. full size. Editor: Lingling JEM: Leslie RTP: Michael ReidThe authors of a paper on a mechanism for potential cancer therapies are retracting it after realizing they published some proprietary findings “without permission and agreement from St. Jude Children’s Research Hospital.”

According to the retraction note in Journal of the American Chemical Society, the authors included an X-ray crystal structure and data that were gathered at St. Jude’s and considered the hospital’s intellectual property. On the paper, the last author, Zhengding Su, listed an affiliation at St. Jude and Hubei University of Technology in China, along with Amersino Biodevelop Inc., based in Waterloo, Canada.

Here’s the note for “Efficient Reactivation of p53 in Cancer Cells by a Dual MdmX/Mdm2 Inhibitor:”  Continue reading Intellectual property issues sink cancer paper in JACS

“Most responsible course of action is to retract:” Duplicated images fell prostate cancer paper

International Journal of CancerA study on the cellular interactions underlying prostate cancer has been retracted after a whistleblower pointed out duplicated images in one of the paper’s figures that were “erroneously presented as unique.”

The International Journal of Cancer posted the notice in June. The authors backed the paper’s conclusions but agreed, “the most responsible course of action is to retract.”

The notice reads:

Continue reading “Most responsible course of action is to retract:” Duplicated images fell prostate cancer paper